Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates

Core Viewpoint - Verve Therapeutics reported a quarterly loss of $0.58 per share, which was better than the Zacks Consensus Estimate of a loss of $0.72, indicating a positive earnings surprise of 19.44% [1] Financial Performance - The company achieved revenues of $13.08 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 90.39%, compared to $5.14 million in the same quarter last year [2] - Over the last four quarters, Verve Therapeutics has exceeded consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Verve Therapeutics shares have increased by approximately 11.9% since the beginning of the year, outperforming the S&P 500, which gained 1.3% [3] Future Outlook - The company's earnings outlook will be crucial for determining future stock performance, with current consensus EPS estimates at -$0.71 for the coming quarter and -$2.83 for the current fiscal year [4][7] - The estimate revisions trend for Verve Therapeutics is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Verve Therapeutics belongs, is currently in the top 50% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]